Neoantigen cancer vaccine augments anti-CTLA-4 efficacy.
Salvatori E, Lione L, Compagnone M, Pinto E, Conforti A, Ciliberto G, Aurisicchio L, Palombo F.
npj Vaccines 2022 volume 7, 15.

Genetic Vaccination as a Flexible Tool to Overcome the Immunological Complexity of Invasive Fungal Infections. 
Luberto L, Neroni B, Gandini O, Fiscarelli EV, Salvatori G, Roscilli G, Marra E.
Front Microbiol 2021 Dec 15;12:789774. doi: 10.3389/fmicb.2021.789774

The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression.
Maffei M, Montemiglio LC, Vitagliano G, Fedele L, Sellathurai S, Bucci F, Compagnone C, Chiarini V, Exertier C, Muzi A, Roscilli G, Vallone B, Marra E.
Biomolecules 2021, 11(12), 1812;

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.
Conforti A et al.
Mol Ther 2022 Jan 5;30(1):311-326. doi: 10.1016/j.ymthe.2021.09.011.

Toxicity and Local Tolerance of COVID- e Vax, a Plasmid DNA Vaccine for SARS-CoV-2, Delivered by Electroporation.
Ramot Y, Caselli G, Aurisicchio L, Andreini I, Marra E, Luberto L, Stoppoloni D,  Pacello ML, Monetini L, Nyska A.
Toxicol Pathol 2021 Oct;49(7):1255-1268.  doi: 10.1177/01926233211042263. Epub 2021 Sep 8.

Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition.
Lione L, Salvatori E, Petrazzuolo A, Massacci A, Maggio R, Conforti A, Compagnone M, Aurisicchio L, Ciliberto G, Palombo F.
Oncoimmunology. 2021; 10(1): 1898832. doi: 10.1080/2162402X.2021.1898832

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, Marra E.
J Transl Med 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.

Are Genetic Vaccines the Right Weapon against COVID-19?
Conforti A,  Marra E, Roscilli G, Palombo F, Ciliberto G, Aurisicchio L.
Mol Ther 2020 Jul 8;28(7):1555-1556. doi: 10.1016/j.ymthe.2020.06.007. Epub 2020 Jun 10.

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L, Salvatori E, Lione L, Bandini S, Pallocca M, Maggio R, Fanciulli M, De Nicola F, Goeman F, Ciliberto G, Conforti A, Luberto L, Palombo F.
J Exp Clin Cancer Res 2019, 14;38(1):78.

The perfect personalized cancer therapy: cancer vaccines against neoantigens.
Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.
J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1

Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Pala D, Rivara S, Mor M, Milazzo FM, Roscilli G, Pavoni E, Giannini G. Glycobiology. 2016 Jun;26(6):640-54. doi: 10.1093/glycob/cww003. Epub 2016 Jan 13.

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS.
Oncogene. 2016 Mar 3;35(9):1206. doi: 10.1038/onc.2015.418. No abstract available.

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, Mariotta S, Giarnieri E, Giovagnoli MR, Torrisi MR, Bergantino F, Costantini S, Fenizia F, Lambiase M, Aurisicchio L, Normanno N, Ciliberto G, Mancini R.
J Transl Med. 2016 Feb 29;14:61. doi: 10.1186/s12967-016-0816-x.

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C, Di Gennaro E, Ciliberto G, Roscilli G, Aurisicchio L, Marra E, Mancini R, Budillon A, Leone A.
Oncotarget. 2016 Feb 4. doi: 10.18632/oncotarget.7195. [Epub ahead of print]

Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. Vesci L, Milazzo FM, Anastasi AM, Petronzelli F, Chiapparino C, Carollo V, Roscilli G, Marra E, Luberto L, Aurisicchio L, Pacello ML, Spagnoli LG, De Santis R.
Oncotarget. 2016 Jan 5;7(1):914-28. doi: 10.18632/oncotarget.6089.

Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Aurisicchio L, Calogero RA, Cavallo F.
Cancer Res. 2016 Jan 1;76(1):62-72. doi: 10.1158/0008-5472.CAN-15-1208. Epub 2015 Nov 13.

Epigenetic silencing of miR-145-5p contributes to brain metastasis. Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pompili A, Carosi MA, Pescarmona E, Segatto O, Pond G, Muti P, Telera S, Strano S, Yarden Y, Blandino G.
Oncotarget. 2015 Nov 3;6(34):35183-201. doi: 10.18632/oncotarget.5930.

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G.
Oncotarget. 2015 Sep 22;6(28):24823-41. doi: 10.18632/oncotarget.4485.

Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. Vesci L, Carollo V, Roscilli G, Aurisicchio L, Ferrara FF, Spagnoli L, De Santis R.
Oncol Rep. 2015 Sep;34(3):1146-52. doi: 10.3892/or.2015.4074. Epub 2015 Jun 24. Erratum in: Oncol Rep. 2016 Jan;35(1):602.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT.
Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. No abstract available.

Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L.
Cancer Immunol Immunother. 2015 Oct;64(10):1305-14. doi: 10.1007/s00262-015-1698-0. Epub 2015 May 6.

Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen. Aurisicchio L, Roscilli G, Marra E, Luberto L, Mancini R, La Monica N, Ciliberto G.
Hum Gene Ther. 2015 Jun;26(6):386-98. doi: 10.1089/hum.2014.141.

The importance of comparative oncology in translational medicine. Riccardo F, Aurisicchio L, Impellizeri JA, Cavallo F.
Cancer Immunol Immunother. 2015 Feb;64(2):137-48. doi: 10.1007/s00262-014-1645-5. Epub 2014 Dec 30. Review.

Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. De Santis R, Rosi A, Anastasi AM, Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D, Carollo V, Marra E, Aurisicchio L, Arseni B, Pacello ML, Palmieri G, Battella S, Petronzelli F, Milazzo FM.
Oncotarget. 2014 Oct 15;5(19):9239-55.

Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC.
Cancer Res. 2014 Sep 15;74(18):5184-94. doi: 10.1158/0008-5472.CAN-14-0663. Epub 2014 Aug 6.

Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis.  Marra E, Sousa VL, Gaziano R, Pacello ML, Arseni B, Aurisicchio L, De Santis R, Salvatori G.
Antimicrob Agents Chemother. 2014 Oct;58(10):6284-6. doi: 10.1128/AAC.03038-14. Epub 2014 Jul 28.

Xenogene vaccination in the therapy of cancer. Cavallo F, Aurisicchio L, Mancini R, Ciliberto G.
Expert Opin Biol Ther. 2014 Oct;14(10):1427-42. doi: 10.1517/14712598.2014.927433. Epub 2014 Jul 15. Review.

A novel minigene scaffold for therapeutic cancer vaccines.  Aurisicchio L, Fridman A, Bagchi A, Scarselli E, La Monica N, Ciliberto G.
Oncoimmunology. 2014 Jan 1;3(1):e27529. Epub 2014 Jan 16.

Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients.  Roscilli G, Cappelletti M, De Vitis C, Ciliberto G, Di Napoli A, Ruco L, Mancini R, Aurisicchio L.
J Transl Med. 2014 Feb 24;12:54. doi: 10.1186/1479-5876-12-54.

Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells.  Noto A, Raffa S, De Vitis C, Roscilli G, Malpicci D, Coluccia P, Di Napoli A, Ricci A, Giovagnoli MR, Aurisicchio L, Torrisi MR, Ciliberto G, Mancini R. Cell Death Dis. 2013 Dec 5;4:e947. doi: 10.1038/cddis.2013.444.

Immunogenicity and Therapeutic Efficacy of a Dual-Component Genetic Cancer Vaccine Cotargeting Carcinoembryonic Antigen and HER2/neu in Preclinical Models. Aurisicchio L, Peruzzi D, Koo G, Wei WZ, La Monica N, Ciliberto G. Hum Gene Ther. 2014 Feb;25(2):121-31. doi: 10.1089/hum.2013.103. Epub 2013 Dec 21.

New developments in cancer vaccines. Buonaguro L, Aurisicchio L, Buonaguro FM, Ciliberto G. Expert Rev Vaccines. 2013 Oct;12(10):1109-10. doi: 10.1586/17476348.2013.838013.

Cancer vaccination by electro-gene-transfer. Aurisicchio L, Mancini R, Ciliberto G. Expert Rev Vaccines. 2013 Oct;12(10):1127-37. doi: 10.1586/14760584.2013.836903. Epub 2013 Sep 25.

Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L. Hum Gene Ther. 2013 Aug;24(8):728-38. doi: 10.1089/hum.2013.112.

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L, D'Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L, Mancini R, Ciliberto G. Oncotarget. 2013 Aug;4(8):1253-65.

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto PA, Ciliberto G. J Transl Med. 2013 Jul 27;11:180. doi: 10.1186/1479-5876-11-180.

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ. J Transl Med. 2013 Mar 8;11:62. doi: 10.1186/1479-5876-11-62.

Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model. Roscilli G, Marra E, Mori F, Di Napoli A, Mancini R, Serlupi-Crescenzi O, Virmani A, Aurisicchio L, Ciliberto G. J Cell Biochem. 2013 Jul;114(7):1665-73. doi: 10.1002/jcb.24508.

An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform. Fridman A, Finnefrock AC, Peruzzi D, Pak I, La Monica N, Bagchi A, Casimiro DR, Ciliberto G, Aurisicchio L.Oncoimmunology. 2012 Nov 1;1(8):1258-1270.

Intrablastocyst injection with human CD34+/CD133+ cells increase survival of immunocompetent fumarylacetoacetate hydrolase knockout mice. Marra E, Turrini P, Tripodi M, Ciliberto G, Padron J, Aurisicchio L. Lab Anim. 2012 Oct;46(4):280-6. doi: 10.1258/la.2012.012038.

Electro-gene-transfer as a new tool for cancer immunotherapy in animals. Impellizeri JA, Ciliberto G, Aurisicchio L. Vet Comp Oncol. 2012 Oct 25. doi: 10.1111/vco.12006.

The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G. Oncotarget. 2012 Aug;3(8):744-58. Review.

Genetic cancer vaccines: current status and perspectives. Aurisicchio L, Ciliberto G. Expert Opin Biol Ther. 2012 Aug;12(8):1043-58. doi: 10.1517/14712598.2012.689279. Epub 2012 May 12. Review.

Kinesin spindle protein SiRNA slows tumor progression. Marra E, Palombo F, Ciliberto G, Aurisicchio L. J Cell Physiol. 2013 Jan;228(1):58-64. doi: 10.1002/jcp.24103.

Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Belleudi F, Marra E, Mazzetta F, Fattore L, Giovagnoli MR, Mancini R, Aurisicchio L, Torrisi MR, Ciliberto G. Cell Cycle. 2012 Apr 1;11(7):1455-67. doi: 10.4161/cc.19861. Epub 2012 Apr 1.

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, Gunes Z, Roscilli G, Mesiti G, Mancini R, Alimandi M, Ciliberto G. J Cell Physiol. 2012 Oct;227(10):3381-8. doi: 10.1002/jcp.24037.

Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment. Mancini R, Giarnieri E, De Vitis C, Malanga D, Roscilli G, Noto A, Marra E, Laudanna C, Zoppoli P, De Luca P, Affuso A, Ruco L, Di Napoli A, Mesiti G, Aurisicchio L, Ricci A, Mariotta S, Pisani L, Andreetti C, Viglietto G, Rendina EA, Giovagnoli MR, Ciliberto G. PLoS One. 2011;6(7):e21320. doi: 10.1371/journal.pone.0021320. Epub 2011 Jul 18.

Intratumor RNA interference of cell cycle genes slows down tumor progression. Dharmapuri S, Peruzzi D, Marra E, Palombo F, Bett AJ, Bartz SR, Yong M, Ciliberto G, La Monica N, Buser CA, Toniatti C, Aurisicchio L. Gene Ther. 2011 Jul;18(7):727-33. doi: 10.1038/gt.2011.27. Epub 2011 Mar 10.

Emerging cancer vaccines: the promise of genetic vectors. Aurisicchio L, Ciliberto G. Cancers (Basel). 2011 Sep 22;3(3):3687-713. doi: 10.3390/cancers3033687.

A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. Mol Ther. 2010 Aug;18(8):1559-67. doi: 10.1038/mt.2010.104. Epub 2010 Jun 8.

Patented cancer vaccines: the promising leads. Aurisicchio L, Ciliberto G. Expert Opin Ther Pat. 2010 May;20(5):647-60. doi: 10.1517/13543771003720483. Review.

A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L. Vaccine. 2010 Apr 30;28(20):3522-30. doi: 10.1016/j.vaccine.2010.03.020.

Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Vaccine. 2010 Feb 3;28(5):1201-8. doi: 10.1016/j.vaccine.2009.11.031. Epub 2009 Nov 26.

Engineered adenovirus serotypes for overcoming anti-vector immunity. Dharmapuri S, Peruzzi D, Aurisicchio L. Expert Opin Biol Ther. 2009 Oct;9(10):1279-87. doi: 10.1517/14712590903187053. Review.

Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, Kandimalla ER, Agrawal S, Scarselli E, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Mol Ther. 2009 Oct;17(10):1804-13. doi: 10.1038/mt.2009.165. Epub 2009 Jul 21.

MMP11: a novel target antigen for cancer immunotherapy. Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N, Aurisicchio L. Clin Cancer Res. 2009 Jun 15;15(12):4104-13. doi: 10.1158/1078-0432.CCR-08-3226. Epub 2009 Jun 9.

 Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. Roscilli G, Cappelletti M, De Vitis C, Ciliberto G, Di Napoli A, Ruco L, Mancini R, Aurisicchio L.
J Transl Med. 2014 Feb 24;12:54. doi: 10.1186/1479-5876-12-54.